US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

Avalyn Pharma (AVLN): Pulmonary Fibrosis IPO Drawing Strong Demand Despite Comp Underperformance

Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Avalyn Pharma Inc. advancing inhaled antifibrotics, led by Phase 2b AP01, targeting pulmonary fibrosis with improved efficacy and tolerability versus oral standards of care.</li>
<li>Backed by top-tier investors including Novo Holdings A/S, IPO filed April 8 with potential late-April debut as roadshow timing approaches.</li>
<li>Strong clinical momentum with multiple programs (AP01, AP02, AP03), supported by long-term data, large unmet need, and potential standalone or combination use in ILD treatment.</li>
</ul>


Avalyn Pharma Inc. advancing inhaled antifibrotics, led by Phase 2b AP01, targeting pulmonary fibrosis with improved efficacy and tolerability versus oral standards of care.
Backed by top-tier investors including Novo Holdings A/S, IPO filed April 8 with potential late-April debut as roadshow timing approaches.
Strong clinical momentum with multiple programs (AP01, AP02, AP03), supported by long-term data, large unmet need, and potential standalone or combination use in ILD treatment.


Avalyn Pharma (AVLN): Peeking at the IPO Prospectus of a Biotech Treating Respiratory Diseases